Liquidia Corporation (NASDAQ:LQDA) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET

Company Participants

Jason Adair - Chief Business Officer

Roger Jeffs - Chief Executive Officer

Rusty Schundler - General Counsel

Mike Kaseta - Chief Financial Officer

Rajeev Saggar - Chief Medical Officer

Conference Call Participants

Mary Kate - Bank of America

Julian Harrison - BTIG

Serge Belanger - Needham

Kambiz Yazdi - Jefferies

Matthew Kaplan - Ladenburg Thalmann

Operator

Good morning, and welcome everyone to the Liquidia Corporation Second Quarter 2023 Financial Results and Corporate Update Conference Call. My name is Livia, and I will be your conference operator today. Currently, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up for questions. I would like to remind everyone that this conference call is being recorded.

I will now hand the conference call over to Jason Adair, Chief Business Officer.

Jason Adair

Thank you, Livia. It's my pleasure to welcome everyone to Liquidia's second quarter 2023 financial results and corporate update conference call.

Joining the call today are Chief Executive Officer, Dr. Roger Jeffs; Chief Financial Officer, Michael Kaseta; General Counsel, Rusty Schundler; and Chief Medical Officer, Dr. Rajeev Saggar.

Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results or performance to be materially different from any future results or performance expressed or implied on this call.

For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website.

I would now like to turn the call over to Roger for our prepared remarks, after which, he will open-up the call up for your questions.

Roger Jeffs

Good morning, everyone and thank you for joining us.

In our opening remarks. Today, we're going to take a very focused approach to address the issue that is most top of mind for our company, our employees, and our shareholders, specifically the path forward as we see it, to the successful resolution after litigation and launch of YUTREPIA for both PAH and PH-ILD.